Rapid publication ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway

Mitsuyo Shintani, Yoshihiro Ogawa, Ken Ebihara, Megumi Aizawa-Abe, Fumiko Miyanaga, Kazuhiko Takaya, Tatsuya Hayashi, Gen Inoue, Kiminori Hosoda, Masayasu Kojima, Kenji Kangawa, Kazuwa Nakao

Research output: Contribution to journalArticle

735 Citations (Scopus)

Abstract

Ghrelin, an endogenous ligand for growth hormone secretagogue (GHS) receptor originally isolated from the stomach, occurs in the hypothalamic arcuate nucleus and may play a role in energy homeostasis. Synthetic GHSs have activated the hypothalamic arcuate neurons containing neuropeptide Y (NPY), suggesting the involvement of NPY in some of ghrelin actions. This study was designed to elucidate the role of ghrelin in the regulation of food intake. A single intracerebroventricular (ICV) injection of ghrelin (5-5,000 ng/rat) caused a significant and dose-related increase in cumulative food intake in rats. Ghrelin (500 ng/rat) was also effective in growth hormone-deficient spontaneous dwarf rats. Hypothalamic NPY mRNA expression was increased in rats that received a single ICV injection of ghrelin (500 ng/rat)( ∼ 6 160% of that in vehicle-treated groups, P < 0.05). The ghrelin's orexigenic effect was abolished dose-dependently by ICV co-injection of NPY Y1 receptor antagonist (10-30 μg/rat). The leptin-induced inhibition of food intake was reversed by ICV co-injection of ghrelin in a dose-dependent manner (5-500 ng/rat). Leptin reduced hypothalamic NPY mRNA expression by 35% (P < 0.05), which was abolished by ICV co-injection of ghrelin (500 ng/rat). This study provides evidence that ghrelin is an orexigenic peptide that antagonizes leptin action through the activation of hypothalamic NPY/Y1 receptor pathway.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalDiabetes
Volume50
Issue number2
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

Ghrelin
Leptin
Growth Hormone
Publications
Peptides
Neuropeptide Y
Injections
Eating
neuropeptide Y-Y1 receptor
Ghrelin Receptor
Appetite Regulation
Messenger RNA
Arcuate Nucleus of Hypothalamus
Stomach
Homeostasis
Ligands
Neurons

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Rapid publication ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. / Shintani, Mitsuyo; Ogawa, Yoshihiro; Ebihara, Ken; Aizawa-Abe, Megumi; Miyanaga, Fumiko; Takaya, Kazuhiko; Hayashi, Tatsuya; Inoue, Gen; Hosoda, Kiminori; Kojima, Masayasu; Kangawa, Kenji; Nakao, Kazuwa.

In: Diabetes, Vol. 50, No. 2, 01.01.2001, p. 227-232.

Research output: Contribution to journalArticle

Shintani, Mitsuyo ; Ogawa, Yoshihiro ; Ebihara, Ken ; Aizawa-Abe, Megumi ; Miyanaga, Fumiko ; Takaya, Kazuhiko ; Hayashi, Tatsuya ; Inoue, Gen ; Hosoda, Kiminori ; Kojima, Masayasu ; Kangawa, Kenji ; Nakao, Kazuwa. / Rapid publication ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. In: Diabetes. 2001 ; Vol. 50, No. 2. pp. 227-232.
@article{9aa873a354634a28a6fc3dd08e01835e,
title = "Rapid publication ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway",
abstract = "Ghrelin, an endogenous ligand for growth hormone secretagogue (GHS) receptor originally isolated from the stomach, occurs in the hypothalamic arcuate nucleus and may play a role in energy homeostasis. Synthetic GHSs have activated the hypothalamic arcuate neurons containing neuropeptide Y (NPY), suggesting the involvement of NPY in some of ghrelin actions. This study was designed to elucidate the role of ghrelin in the regulation of food intake. A single intracerebroventricular (ICV) injection of ghrelin (5-5,000 ng/rat) caused a significant and dose-related increase in cumulative food intake in rats. Ghrelin (500 ng/rat) was also effective in growth hormone-deficient spontaneous dwarf rats. Hypothalamic NPY mRNA expression was increased in rats that received a single ICV injection of ghrelin (500 ng/rat)( ∼ 6 160{\%} of that in vehicle-treated groups, P < 0.05). The ghrelin's orexigenic effect was abolished dose-dependently by ICV co-injection of NPY Y1 receptor antagonist (10-30 μg/rat). The leptin-induced inhibition of food intake was reversed by ICV co-injection of ghrelin in a dose-dependent manner (5-500 ng/rat). Leptin reduced hypothalamic NPY mRNA expression by 35{\%} (P < 0.05), which was abolished by ICV co-injection of ghrelin (500 ng/rat). This study provides evidence that ghrelin is an orexigenic peptide that antagonizes leptin action through the activation of hypothalamic NPY/Y1 receptor pathway.",
author = "Mitsuyo Shintani and Yoshihiro Ogawa and Ken Ebihara and Megumi Aizawa-Abe and Fumiko Miyanaga and Kazuhiko Takaya and Tatsuya Hayashi and Gen Inoue and Kiminori Hosoda and Masayasu Kojima and Kenji Kangawa and Kazuwa Nakao",
year = "2001",
month = "1",
day = "1",
doi = "10.2337/diabetes.50.2.227",
language = "English",
volume = "50",
pages = "227--232",
journal = "Diabetes",
issn = "0012-1797",
publisher = "医学出版",
number = "2",

}

TY - JOUR

T1 - Rapid publication ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway

AU - Shintani, Mitsuyo

AU - Ogawa, Yoshihiro

AU - Ebihara, Ken

AU - Aizawa-Abe, Megumi

AU - Miyanaga, Fumiko

AU - Takaya, Kazuhiko

AU - Hayashi, Tatsuya

AU - Inoue, Gen

AU - Hosoda, Kiminori

AU - Kojima, Masayasu

AU - Kangawa, Kenji

AU - Nakao, Kazuwa

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Ghrelin, an endogenous ligand for growth hormone secretagogue (GHS) receptor originally isolated from the stomach, occurs in the hypothalamic arcuate nucleus and may play a role in energy homeostasis. Synthetic GHSs have activated the hypothalamic arcuate neurons containing neuropeptide Y (NPY), suggesting the involvement of NPY in some of ghrelin actions. This study was designed to elucidate the role of ghrelin in the regulation of food intake. A single intracerebroventricular (ICV) injection of ghrelin (5-5,000 ng/rat) caused a significant and dose-related increase in cumulative food intake in rats. Ghrelin (500 ng/rat) was also effective in growth hormone-deficient spontaneous dwarf rats. Hypothalamic NPY mRNA expression was increased in rats that received a single ICV injection of ghrelin (500 ng/rat)( ∼ 6 160% of that in vehicle-treated groups, P < 0.05). The ghrelin's orexigenic effect was abolished dose-dependently by ICV co-injection of NPY Y1 receptor antagonist (10-30 μg/rat). The leptin-induced inhibition of food intake was reversed by ICV co-injection of ghrelin in a dose-dependent manner (5-500 ng/rat). Leptin reduced hypothalamic NPY mRNA expression by 35% (P < 0.05), which was abolished by ICV co-injection of ghrelin (500 ng/rat). This study provides evidence that ghrelin is an orexigenic peptide that antagonizes leptin action through the activation of hypothalamic NPY/Y1 receptor pathway.

AB - Ghrelin, an endogenous ligand for growth hormone secretagogue (GHS) receptor originally isolated from the stomach, occurs in the hypothalamic arcuate nucleus and may play a role in energy homeostasis. Synthetic GHSs have activated the hypothalamic arcuate neurons containing neuropeptide Y (NPY), suggesting the involvement of NPY in some of ghrelin actions. This study was designed to elucidate the role of ghrelin in the regulation of food intake. A single intracerebroventricular (ICV) injection of ghrelin (5-5,000 ng/rat) caused a significant and dose-related increase in cumulative food intake in rats. Ghrelin (500 ng/rat) was also effective in growth hormone-deficient spontaneous dwarf rats. Hypothalamic NPY mRNA expression was increased in rats that received a single ICV injection of ghrelin (500 ng/rat)( ∼ 6 160% of that in vehicle-treated groups, P < 0.05). The ghrelin's orexigenic effect was abolished dose-dependently by ICV co-injection of NPY Y1 receptor antagonist (10-30 μg/rat). The leptin-induced inhibition of food intake was reversed by ICV co-injection of ghrelin in a dose-dependent manner (5-500 ng/rat). Leptin reduced hypothalamic NPY mRNA expression by 35% (P < 0.05), which was abolished by ICV co-injection of ghrelin (500 ng/rat). This study provides evidence that ghrelin is an orexigenic peptide that antagonizes leptin action through the activation of hypothalamic NPY/Y1 receptor pathway.

UR - http://www.scopus.com/inward/record.url?scp=0035143816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035143816&partnerID=8YFLogxK

U2 - 10.2337/diabetes.50.2.227

DO - 10.2337/diabetes.50.2.227

M3 - Article

C2 - 11272130

AN - SCOPUS:0035143816

VL - 50

SP - 227

EP - 232

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 2

ER -